NBSE News and Press, NeuBase Therapeutics Inc. From 05/02/23

PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepte...

NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q1 GAAP EPS of -$0.13 misses by $0.02 . As of December 31, 2022, the Company had cash and cash equivalents of approximately $17.4 million, compared with approximately $23.2 million as of September 30, 2022. NeuBase estim...

PITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, tod...

Penny Stocks Under $1 To Watch This Week unless you’ve been living under a rock, you know how bearish the stock market is right now. Since the beginning of the year, major indexes are trading lower. While some are dipping more than others, market participants are finding different ways...

NeuBase Therapeutics press release ( NASDAQ: NBSE ): FY GAAP EPS of -$1.04 beats by $0.04 . As of September 30, 2022, the Company had cash and cash equivalents of approximately $23.2 million, compared with approximately $52.9 million as of September 30, 2021. Shares +5% ...

PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, tod...

NeuBase Therapeutics ( NASDAQ: NBSE ) on Friday said it signed a gene editing research agreement with one of the top 10 global healthcare companies. The healthcare company will evaluate NeuBase's PATrOL technology for three monogenic genetic diseases. PATrOL is a pepti...

PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicine...

NeuBase Therapeutics ( NASDAQ: NBSE ) on Friday announced a strategic restructuring to focus on its gene editing platform, including ~60% job cuts and a cost reduction plan that will extend its cash runway into Q2 CY24. Shares of NBSE, which ended 9.7% lower on ...

Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company’s cash runway into Q2 CY2024 The Company plans to maximize shareholder value by focusing R&D resources on advancement of the differentiated gene editing ...